Labmaster LUCIA™ human IVD tests
Labmaster Ltd developes human IVD tests based on Cathodic Electrochemiluminescence (C-ECL) technology
Human IVD tests & pipeline
Launched 2021
Labmaster LUCIA™ CRP
Launched 2021
Labmaster LUCIA™ MxA
Labmaster LUCIA™ SARS-CoV-2 IgG (NP), launch: Winter 2021-22
for the qualitative determination of present or past immune response to SARS-CoV-2 virus exposure in whole blood samples.
Labmaster LUCIA™ SARS-CoV-2 IgG (RBD), launch: Winter 2021-22
for the qualitative determination of present or past immune response to SARS-CoV-2 virus exposure or vaccination efficiency in whole blood samples. The test is suited for monitoring COVID-19 vaccines that are based on SARS-CoV-2 spike-protein producing systems.
Labmaster LUCIA™ SARS-CoV-2 (NAB), launch: Winter 2021-22
for the qualitative determination of SARS-CoV-2 neutralizing antibodies (NAB) in the whole blood samples.
Labmaster LUCIA™ HbA1c (Glycated Hemoglobin), launch: Spring 2022
for the quantitative determination of Hemoglobin A1c in whole blood samples